Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.673 SEK | -1.18% | -2.91% | -65.14% |
Sales 2024 * | 82.38M 7.73M 10.57M | Sales 2025 * | 196M 18.37M 25.11M | Capitalization | 593M 55.68M 76.12M |
---|---|---|---|---|---|
Net income 2024 * | -244M -22.9M -31.3M | Net income 2025 * | -174M -16.33M -22.32M | EV / Sales 2024 * | 5.52 x |
Net cash position 2024 * | 138M 12.98M 17.75M | Net Debt 2025 * | 62.58M 5.87M 8.03M | EV / Sales 2025 * | 3.35 x |
P/E ratio 2024 * |
-1.77
x | P/E ratio 2025 * |
-2.59
x | Employees | 57 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.37% |
Latest transcript on Oncopeptides AB
1 day | +0.37% | ||
1 week | -2.70% | ||
Current month | -7.04% | ||
1 month | -8.46% | ||
3 months | -48.50% | ||
6 months | -68.62% | ||
Current year | -64.69% |
Managers | Title | Age | Since |
---|---|---|---|
Sofia Heigis
CEO | Chief Executive Officer | 44 | 20-07-31 |
Director of Finance/CFO | 50 | 11-12 | |
Eva Nordström
COO | Chief Operating Officer | 54 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Per Wold-Olsen
CHM | Chairman | 76 | 18-05-16 |
Director/Board Member | 63 | 11-12-31 | |
Director/Board Member | 61 | 17-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-27 | 2.67 | -1.29% | 319 601 |
24-05-24 | 2.705 | +0.37% | 807,406 |
24-05-23 | 2.695 | -0.92% | 1,012,590 |
24-05-22 | 2.72 | -2.51% | 1,885,695 |
24-05-21 | 2.79 | +1.45% | 1,197,190 |
Delayed Quote Nasdaq Stockholm, May 24, 2024 at 11:29 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.69% | 55.73M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.34% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- ONCO Stock